

6th INTERNATIONAL LUNG CANCER SUMMIT

4 OCTOBER 2024 LUNGCANCERSUMMIT.ORG



Lausanne
University
Hospital



Hôpitaux
Universitaires
Genève



TENTATIVE AGENDA 2024

10.00	Welcome & Introduction	S. Peters & A. Addeo	Switzerland
10.02	Advancements in Lung Cancer Diagnostics: Current Guidelines and Emerging Tests	Keith Kerr	UK
10.30	Novel Therapeutic Options in Targeting EGFR and ALK Beyond Osimertinib and Alectinib	Anne-Marie Dingemans	Netherlands
10.50	Rare But Actionable: How To Target for RET, METex14 and NTRK	Roberto Ferrara	Italy
11.15	BREAK		
11.40	Decoding Actionable Alterations: Insights from KRAS, HER2, and c-MET	Biagio Ricciuti	USA
12.05	The Emerging Role of ADCs in Lung Cancer: Navigating Timing and Applications for Optimal Use	Jarushka Naidoo	Ireland
12.30	SATELLITE INDUSTRY SYMPOSIA		
14.00	Surgical Dilemmas in NSCLC: Defining Resectability for Optimal Patient Outcomes in the IO Era	Nuria Maria Novoa	Spain
14.30	Tailoring IO in Resectable NSCLC: Personalized Approaches for Improved Outcomes	Delvys Rodriguez Abreu	Spain
15.00	BREAK		
15.20	DEBATE: Balancing Efficacy, Toxicity, and Patient-Centered Care For IO Duration in NSCLC • We Must Seize Every Opportunity To Cease IO • We Must Maximize IO Benefits Through Prolonged Therapy	Giannis Mountzios Sandip Patel	Greece USA
15.50	Reshaping Our Approaches in SCLC: Latest Therapeutic Options and Future Strategies	Stephen Liu	USA
16.15	Panel Discussion: Open Questions, Patient Cases & Guidelines	All Speakers & Attendees	

ALL SPEAKERS ARE IASLC MEMBERS AND CONFIRMED.
THIS CONFERENCE IS INTERNATIONALLY ACCREDITED AND ENDORSED BY



European Accreditation Council
for Continuing Medical Education
(EACCME)
An Institution of the UEMS